Expression of HLA-DR antigens on tumour cells does not contribute to skin reactivity to autologous cholesteryl hemisuccinate (CHS)-treated tumour cells in patients with metastatic melanoma.
Skin tests with autologous cholesteryl hemisuccinate (CHS)-treated and untreated cells were performed in ten metastatic melanoma patients. In the majority of cases evident reaction was noted with CHS-treated cells (9/10) while the reaction with untreated cells was mostly negative (7/10). Tumour cell suspensions used for skin tests were characterized for reactivity with monoclonal antibody TAL 1B5 detecting the HLA-DR alpha chain. There were no differences between CHS-treated and untreated cells with respect to HLA-DR expression and no correlation was found between grade of skin reaction to CHS-treated cells and the proportion of HLA-DR positive cells in the injected cell sample.
D000951:Antigens, Neoplasm / Q000276:immunology*; D002788:Cholesterol Esters / Q000494:pharmacology; D006681:HLA-D Antigens / Q000276:immunology*; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D007109:Immunity; D008545:Melanoma / Q000276:immunology*; D012882:Skin Tests
D000951:Antigens, Neoplasm; D002788:Cholesterol Esters; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; C013440:cholesteryl succinate